Dendritic cell-based immunotherapy for malignant gliomas

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 497-508

  Akasaki, Yasuharu ^a   Black, Keith L ^a   Yu, John S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

CNS; Cytotoxic T lymphocyte; Dendritic cells; Glioma; Immunotherapy; T helper cell; T regulatory cell; Tumor associated antigen

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; DENDRITIC CELL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 12; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL HETEROGENEITY; CELL INTERACTION; CELL POPULATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; NONHUMAN; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; BRAIN NEOPLASMS; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 22544482636     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.497     Document Type: Review

References (125)

1. Legler JM, Ries LA, Smith MA et al. Cancer surveillance series (corrected): brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 91, 1382-1390 (1999).
2. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J. Neurooncol. 40, 151-160 (1998).
3. Ehtesham M, Samoto K, Kabos P et al. Treatment of intracranial glioma with in situ interferon-γ and tumor necrosis factor-α gene transfer. Cancer Gene Ther. 9, 925-934 (2002).
4. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90, 1115-1124 (1999).
5. Liu Y, Ehtesham M, Samoto K et al. In situ adenoviral interleukin-12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 9, 9-15 (2002).
6. Herrlinger U, Kramm CM, Johnston KM et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther. 4, 345-352 (1997).
7. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507-512 (1992).
8. Becher B, Prat A, Antel JP. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29, 293-304 (2000).
9. Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 11, 125-137 (1999). Focuses on the functional roles of leukocyte trafficking into the CNS.
10. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T-cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191, 761-770 (2000).
11. Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol. 11, 92-106 (2001).
12. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli, E, Nicholson LB. T-cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T-cell repertoire. Ann. Rev. Immunol. 20, 101-123 (2002).
13. Adorini L. Immunotherapeutic approaches in multiple sclerosis. J. Neurol. Sci. 223, 13-24 (2004).
14. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol. 156, 3-9 (2004).
15. Qing Z, Sewell D, Sandor M, Fabry Z. Antigen-specific T-cell trafficking into the central nervous system. J. Neuroimmunol. 105, 169-178 (2000).
16. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α4 integrin by CD4 T-cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57-68, 1993.
17. Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T lymphocyte final effector function and death. J. Exp. Med. 184, 1737-1745 (1996).
18. Irani DN. Brain-derived gangliosides induce cell cycle arrest in a murine T-cell line. J. Neuroimmunol. 87, 11-16 (1998).
19. Wilbanks GA Streilein JW. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-β. Eur. J. Immunol. 22, 1031-1036 (1992).
20. Suvannavejh GC, Dal Canto MC, Matis LA, Miller SD. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105, 223-231 (2000).
21. Bauer J, Bradl M, Hickley WF et al. T-cell apoptosis in inflammatory brain lesions: destruction of T-cells does not depend on antigen recognition. Am. J. Pathol. 153, 715-724 (1998).
22. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 75, 165-173 (1997).
23. Merrill JE, Murphy SP. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav. Immun. 11, 245-263 (1997).
24. + T-lymphocytes. Blood 105(5), 2090-2092 (2005).
25. Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J. Immunol. 159, 2399-2408 (1997).
26. Walker PR, Calzascia T, Schnuriger V et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T-cells. J. Immunol. 165, 3128-3135 (2000).
27. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 40, 252-259 (2002).
28. Schneider J, Hofman FM, Apuzzo ML, Hinton DR. Cytokines and immunoregulatory molecules in malignant glial neoplasms. J. Neurosurg. 77, 265-273 (1992).
29. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 166, 2717-2726 (2001).
30. Yang T, Witham TF, Villa L et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 62, 2583-2591 (2002).
31. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
32. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin. Immunol. 13, 291-302 (2001).
33. Hart MN, Fabry Z. CNS antigen presentation. Trends Neurosci. 18, 475-481 (1995).
34. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107-116 (2003).
35. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol. Immunother. 51, 424-430 (2002).
36. Imaizumi T, Kuramoto T, Matsunaga K et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int. J. Cancer 83, 760-764 (1999).
37. Murayama K, Kobayashi T, Imaizumi T et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J. Immunother. 23, 511-518 (2000).
38. Nonaka Y, Tsuda N, Shichijo S et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 60, 319-327 (2002).
39. Tsuda N, Nonaka Y, Shichijo S et al. UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T-lymphocytes from patients with brain tumour. Br. J. Cancer 87, 1006-1012 (2002).
40. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201 -restricted, cytotoxic T-lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin. Cancer Res. 8, 2851-2855 (2002).
41. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T-lymphocyte target in patients with malignant glioma. J. Immunother. 26, 301-312 (2003).
42. Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. 27, 220-226 (2004).
43. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T-cells. Cancer Res. 64, 4980-4986 (2004).
44. Pardoll D. Does the immune system see tumors as foreign or self? Ann. Rev. Immunol. 21, 807-839 (2003). Focuses on the mechanism by which cancers escape from host immune defenses.
45. Tacconi L, Stapleton S, Signorelli F, Thomas DG. Acquired immune deficiency syndrome (AIDS) and cerebral astrocytoma. Clin. Neurol. Neurosurg. 98, 149-151 (1996).
46. Wolff R, Zimmermann M, Marquardt G, Lanfermann H, Nafe R, Seifert V. Glioblastoma multiforme of the brain stem in a patient with acquired immunodeficiency syndrome. Acta Neurochir. (Wien) 144, 941-945 (2002).
47. Salvati M, Frati A, Caroli E et al. Glioblastoma in kidney transplant recipients. Report of five cases. J. Neurooncol. 63, 33-37 (2003).
48. Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant glioma. Cancer Control 11, 181-191 (2004).
49. Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10, 138-147 (2003).
50. Ehtesham M, Black KL, Yu JS. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11, 192-207 (2004).
51. Zou JP, Morford LA, Chougnet C et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162, 4882-4892 (1999).
52. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol. Today 12, 370-374 (1991).
53. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21, 128-151 (1995).
54. + T regulatory Type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173, 4352-4359 (2004). Demonstrates the mechanism of T-regulatory cell induction by human malignant glioma.
55. Chaux P, Favre N, Bonnotte B, Moutet M, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv. Exp. Med. Biol. 417, 525-528 (1997).
56. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72, 619-624 (1997).
57. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3, 483-490 (1997).
58. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4, 585-593 (1998).
59. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847 (2001).
60. Yamanaka R, Yajima N, Abe T et al. Dendritic cell-based glioma immunotherapy (review). Int. J. Oncol. 23, 5-15 (2003).
61. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50, 337-344 (2001).
62. Kikuchi T, Abe T, Ohno T. Effects of glioma cells on maturation of dendritic cells. J. Neurooncol. 58, 125-130 (2002).
63. Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ. Intratumoral T-cell subset ratios and Fas ligand expression on brain tumor endothelium. J. Neurooncol. 64, 55-61 (2003).
64. Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63, 7462-7467 (2003).
65. Wiendl H, Mitsdoerffer M, Hofmeister V et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168, 4772-4780 (2002).
66. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 146, 317-322 (1995).
67. Harada M, Matsunaga K, Oguchi Y et al. The involvement of transforming growth factor β in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res. 55, 6146-6151 (1995).
68. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T-regulatory cells. Immunol. Rev. 182, 68-79 (2001).
69. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
70. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
71. Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28, 2780-2790 (1998).
72. + T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196, 1335-1346 (2002).
73. + T-cells. Nature Immunol. 2, 1010-1017 (2001).
74. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191, 411-416 (2000).
75. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann. Rev. Immunol. 21, 685-711 (2003).
76. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000).
77. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell. Biol. 80, 477-483 (2002).
78. + regulatory T-cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235-247 (2003).
79. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168, 2255-2263 (2002).
80. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J. Biol. Chem. 272, 16709-16712 (1997).
81. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375-4381 (2001).
82. Joki T, Heese O, Nikas DC et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60, 4926-4931 (2000).
83. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100, 216-232 (1999).
84. Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br. Med. Bull. 62, 149-162 (2002).
85. Holladay FP, Heitz T, Wood GW. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T-lymphocytes, but not by lymphokine-activated killer cells. J. Neurosurg. 77, 757-762 (1992).
86. Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin. Biol. Ther. 4, 1609-1620 (2004).
87. Fong L, Engleman G. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 18, 245-273 (2000).
88. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8, 1065-1072 (1997).
89. Sobol RE, Fakhrai H, Shawler D et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164-167 (1995).
90. Joki T, Kikuchi T, Akasaki Y, Saitoh S, Abe T, Ohno T. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int. J. Cancer 82, 714-720 (1999).
91. + T-cell activation. Glia 36, 391-405, (2001).
92. Heimberger AB, Crotty LE, Archer GE et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J. Neuroimmunol. 103, 16-25 (2000).
93. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J. Neurosurg. 94, 474-481 (2001).
94. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24, 106-113 (2001).
95. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. 7-hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50, 1327-1335 (2002).
96. Yamanaka R, Yajima N, Tsuchiya N et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J. Neurosurg. 97, 1184-1190 (2002).
97. Saito R, Mizuno M, Nakahara N et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int. J. Cancer 111, 777-782, (2004).
98. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
99. Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol. Med. 7, 659-667 (2001).
100. Fecci PE, Mitchell DA, Archer GE et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J. Neurooncol. 64, 161-176 (2003).
101. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368 (1998).
102. + T-cell memory. Science 297, 2060-2063 (2002).
103. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
104. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
105. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
106. Tatsumi T, Kierstead LS, Ranieri E et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T-cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196, 619-628 (2002).
107. + Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J. Immunol. 170, 1490-1497 (2003).
108. Gately MK, Renzetti LM, Magram J et al. The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol. 16, 495-521 (1998).
109. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann. Rev. Immunol. 19, 423-474 (2001).
110. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T-cell responses. Immunity 19, 641-644 (2003).
111. Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73, 49-56 (2003).
112. Pirhonen J, Matikainen S, Julkunen I. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J. Immunol. 169, 5673-5678 (2002).
113. Belladonna ML, Renauld JC, Bianchi R et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448-5454 (2002).
114. Liu G, Ng H, Akasaki Y et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 34, 1680-1687 (2004). Demonstrated that interleukin-10-suppresses dentritic cells by small interference RNA modulation and enhances tumoricidal T-helper 1 responses.
115. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 19, 683-765 (2001).
116. Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1-14 (1998).
117. Nair SK, Boczkowski D, Morse M, Gumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369 (1998).
118. Jingwu Z, Medaer R, Hashim GA, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 32, 330-338 (1992).
119. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64, 4973-4979 (2004). Phase II clinical trial of dendritic cell-based immunotherapy for glioma patients demonstrating its effectiveness for this disease.
120. Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27, 452-459 (2004). Phase II clinical trial of dendritic cell-based immunotherapy combined with cytokine-therapy of interleukin-12 for glioma patients.
121. Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178, 479-488 (1993).
122. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89, 1172-1179 (2003).
123. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10, 5316-5326 (2004). Demonstrated that dendritic cell-based immunotherapy has a potential to increase the sensitivity to chemotherapeutic drugs.
124. Chu W, Pak BJ, Bani MR et al. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 19, 395-402 (2000).
125. Liu G, Akasaki Y, Khong HT et al. Cytotoxic T-cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) (In Press).